Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus PROGESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELALUTIN versus PROGESTERONE.
DELALUTIN vs PROGESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Progesterone binds to progesterone receptors (PR-A and PR-B) in target tissues, modulating gene expression to induce secretory changes in the endometrium, support pregnancy, and regulate gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
Oral: 200-400 mg daily in 1-2 divided doses; Intramuscular: 50-100 mg daily; Vaginal: 200-400 mg daily in 1-2 divided doses.
None Documented
None Documented
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digoxin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyprogesterone caproate + Digitoxin
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Elimination half-life: approximately 5-15 minutes for intravenous progesterone; terminal half-life of metabolites (pregnanediol) is about 2-8 hours, but clinical effects (e.g., endometrial transformation) persist for days due to receptor-mediated activity.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Renal (50-60% as metabolites) and fecal (10-20%). Biliary excretion of metabolites occurs; enterohepatic recirculation may contribute to prolonged presence. Unchanged drug negligible in urine.
Category C
Category D/X
Progestin
Progestin
"Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digitoxin."